Abstract
The current practice of withdrawing antiplatelet therapy before major surgery has been challenged by the introduction of coronary drug-eluting stents (DESs) since evidence is accumulating that a DES requires dual antiplatelet therapy for at least a year. The authors present a case demonstrating difficulty in decision-making when it comes to appropriate perioperative antiplatelet therapy. The patient experienced a coronary stent thrombosis possibly due to discontinuation of clopidogrel prior to urologic surgery.
MeSH terms
-
Aged
-
Clopidogrel
-
Coronary Stenosis / complications
-
Coronary Stenosis / therapy*
-
Drug-Eluting Stents / adverse effects*
-
Fatal Outcome
-
Humans
-
Immunosuppressive Agents / administration & dosage
-
Lymph Node Excision*
-
Male
-
Paclitaxel / administration & dosage
-
Platelet Aggregation Inhibitors / administration & dosage*
-
Prostatic Neoplasms / complications
-
Prostatic Neoplasms / pathology*
-
Thrombosis / etiology*
-
Ticlopidine / administration & dosage
-
Ticlopidine / analogs & derivatives*
-
Withholding Treatment
Substances
-
Immunosuppressive Agents
-
Platelet Aggregation Inhibitors
-
Clopidogrel
-
Ticlopidine
-
Paclitaxel